Adherence patterns in antiseizure medications influencing risk of sudden unexplained death in epilepsy: A data linkage study using dispensed prescriptions
暂无分享,去创建一个
[1] Wesley T. Kerr,et al. Antiseizure medication adherence trajectories in Medicare beneficiaries with newly treated epilepsy , 2021, Epilepsia.
[2] Josemir W Sander,et al. FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force , 2021, Epilepsia open.
[3] K. Matthews,et al. Medication adherence, utilization of healthcare services, and mortality of patients with epilepsy on opiate replacement therapy: A retrospective cohort study , 2021, Epilepsy & Behavior.
[4] C. Elger,et al. Does the accumulated antiepileptic drug load in chronic epilepsy reflect disease severity? , 2020, Epilepsia.
[5] J. Hallas,et al. Using the waiting time distribution with random index dates to estimate prescription durations in the presence of seasonal stockpiling , 2020, Pharmacoepidemiology and drug safety.
[6] J. Hung,et al. Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients , 2020, Pharmacoepidemiology and drug safety.
[7] S. Patten,et al. Association of Levels of Specialized Care With Risk of Premature Mortality in Patients With Epilepsy. , 2019, JAMA neurology.
[8] Dan Dediu,et al. Beyond Adherence Thresholds: A Simulation Study of the Optimal Classification of Longitudinal Adherence Trajectories From Medication Refill Histories , 2019, Front. Pharmacol..
[9] M. Hiligsmann,et al. Methods for Measuring Multiple Medication Adherence: A Systematic Review-Report of the ISPOR Medication Adherence and Persistence Special Interest Group. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] J. Hung,et al. Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database , 2018, Clinical epidemiology.
[11] E. Roughead,et al. The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System , 2018, BMJ Open.
[12] D. Friedman,et al. Underestimation of sudden deaths among patients with seizures and epilepsy , 2017, Neurology.
[13] T. Tomson,et al. The incidence of SUDEP , 2017, Neurology.
[14] N. Malek,et al. A review of medication adherence in people with epilepsy , 2017, Acta neurologica Scandinavica.
[15] Dan Dediu,et al. Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data , 2017, PloS one.
[16] Edouard Hirsch,et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology , 2017, Epilepsia.
[17] Orrin Devinsky,et al. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention , 2016, The Lancet Neurology.
[18] H. Hamer,et al. Nonadherence to antiepileptic drugs in Germany , 2016, Neurology.
[19] S. Pearson,et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers , 2015, BMC Research Notes.
[20] D. Thurman,et al. Sudden unexpected death in epilepsy: Assessing the public health burden , 2014, Epilepsia.
[21] R. Horne,et al. Patients' perspectives on antiepileptic medication: Relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care , 2014, Epilepsy & Behavior.
[22] I. Abraham,et al. A method for calculating adherence to polypharmacy from dispensing data records , 2013, International Journal of Clinical Pharmacy.
[23] A. Schulze-Bonhage,et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study , 2013, The Lancet Neurology.
[24] V. Allgar,et al. Adherence to medicines and self-management of epilepsy: A community-based study , 2013, Epilepsy & Behavior.
[25] Maochao Xu,et al. Comparison of pharmacy-based measures of medication adherence , 2012, BMC Health Services Research.
[26] R. Bautista,et al. Effects of antiepileptic drug characteristics on medication adherence , 2012, Epilepsy & Behavior.
[27] P. Ryvlin,et al. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials , 2011, The Lancet Neurology.
[28] Josemir W Sander,et al. Combined analysis of risk factors for SUDEP , 2011, Epilepsia.
[29] Samden D Lhatoo,et al. An electroclinical case‐control study of sudden unexpected death in epilepsy , 2010, Annals of neurology.
[30] G. Mathern,et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies , 2009, Epilepsia.
[31] Josemir W. Sander,et al. Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms , 2009, Nature Reviews Neurology.
[32] S. Candrilli,et al. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy , 2009, Epilepsy & Behavior.
[33] E. Faught,et al. Nonadherence to antiepileptic drugs and increased mortality , 2008, Neurology.
[34] Philippe Ryvlin,et al. Sudden unexpected death in epilepsy: current knowledge and future directions , 2008, The Lancet Neurology.
[35] Josemir W Sander,et al. Sudden Unexpected Death in Epilepsy A Personalized Prediction Tool , 2022 .